Deal Library / Pharma BD Deal Intelligence

AstraZeneca PLC — Pharma Deals

The Pharma Closeout tracks 45 deals, $154.0B in disclosed deal value, 32 with a post-close Outcome Score for AstraZeneca PLC.

Median Critic Score: 83  ·  Median Outcome Score: 63

Best outcome: AstraZeneca PLC / Daiichi Sankyo Company, Limited (100)  ·  Weakest outcome: AstraZeneca PLC / Arrow Therapeutics Ltd. (13)

All 45 deals

• AstraZeneca PLC / Daiichi Sankyo Company, Limited — 2019 · $6.9B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Alexion Pharmaceuticals Inc. — 2020 · $39.0B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Acerta Pharma — 2015 · $4.0B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Amgen Inc. — 2020 · $2.3B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / MedImmune Inc. — 2007 · $15.6B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / CinCor Pharma Inc. — 2023 · $1.8B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance — 2012 · $3.5B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd — 2026 · $1.5B · Largely worked — most objectives met.
• AstraZeneca PLC / Amolyt Pharma — 2024 · $1.1B · Largely worked — most objectives met.
• AstraZeneca PLC / Ionis Pharmaceuticals, Inc. — 2021 · $4.2B · Largely worked — most objectives met.
• AstraZeneca PLC / ZS Pharma Inc. — 2015 · $2.7B · Largely worked — most objectives met.
• AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. — 2025 · $2.0B · Largely worked — most objectives met.
• AstraZeneca PLC / Bristol-Myers Squibb diabetes alliance assets — 2013 · $4.3B · Largely worked — most objectives met.
• AstraZeneca PLC / Cambridge Antibody Technology Group plc — 2006 · $1.3B · Largely worked — most objectives met.
• AstraZeneca PLC / Gracell Biotechnologies — 2023 · $1.2B · Largely worked — most objectives met.
• AstraZeneca PLC / Fusion Pharmaceuticals Inc. — 2024 · $2.4B · Largely worked — most objectives met.
• AstraZeneca PLC / TeneoTwo Inc. — 2022 · $1.3B · Largely worked — most objectives met.
• AstraZeneca PLC / Daiichi Sankyo Company, Limited — 2020 · $6.0B · Largely worked — most objectives met.
• AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2026 · $18.5B · Largely worked — most objectives met.
• AstraZeneca PLC / Icosavax Inc. — 2023 · $1.1B · Largely worked — most objectives met.
• AstraZeneca PLC / Pearl Therapeutics Inc. — 2013 · $1.1B · Largely worked — most objectives met.
• AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2026 · $1.8B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Absci Corporation — 2023 · $247M · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / TeneoTwo Inc. — 2022 · $1.3B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Innate Pharma SA — 2018 · $1.3B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Definiens AG — 2014 · $150M · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Takeda Pharmaceutical Company Limited (core respiratory business) — 2015 · $575M · Underwhelmed — fell short of the thesis.
• AstraZeneca PLC / Almirall S.A. (respiratory franchise) — 2014 · $2.1B · Underwhelmed — fell short of the thesis.
• AstraZeneca PLC / Ardea Biosciences, Inc. — 2012 · $1.3B · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Pieris Pharmaceuticals, Inc. — 2017 · $2.2B · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Omthera Pharmaceuticals Inc. — 2013 · $443M · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Arrow Therapeutics Ltd. — 2007 · $150M · Did not work — the deal failed to deliver.
• AstraZeneca PLC / EsoBiotec SA — 2025 · $1.0B
• AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. — 2025 · $2.0B
• AstraZeneca PLC / Harbour BioMed (Nottingham) Ltd. — 2025 · $4.6B
• AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2024 · $2.0B
• AstraZeneca PLC / Quell Therapeutics Limited — 2023 · $2.1B
• AstraZeneca PLC / LaNova Medicines Limited — 2023 · $600M
• AstraZeneca PLC / Cellectis SA — 2023 · $605M
• AstraZeneca PLC / Eccogene (Shanghai) Co., Ltd. — 2023 · $2.0B
• AstraZeneca PLC / Neogene Therapeutics B.V. — 2022 · $320M
• AstraZeneca PLC / Ionis Pharmaceuticals, Inc. — 2021 · $3.6B
• AstraZeneca PLC / Allergan plc — 2020 · $250M
• AstraZeneca PLC / Moderna Therapeutics — 2013 · $420M
• AstraZeneca PLC / Rigel Pharmaceuticals, Inc. (Fostamatinib license) — 2010 · $1.2B

← Deal Library  ·  Interactive search  ·  How we score deals